Over the past two decades, left ventricular assist device (LVAD) support has emerged as
standard therapy for adult patients with advanced, life-threatening heart failure …

Background Continuous-flow left ventricular assist devices (LVADs) cause blood trauma that
includes von Willebrand factor degradation, platelet activation, and subclinical hemolysis …

The management of continuous-flow left ventricular assist devices (LVADs) continues to
evolve. Benefits of pulsatile versus nonpulsatile mechanical circulatory support remain an …

The past five years have seen remarkable growth in the use of durable, continuous flow left
ventricular assist devices (LVAD) with associated improvements in mortality, quality of life …

Mounting evidence points to both arterial pulsatility and pump shear as factors that may be
responsible for the high incidence of nonsurgical bleeding events observed in patients with …

Cardiac transplantation provides definitive management of severe heart failure in selected
patients who have exhausted all other options. The results of transplantation have improved …

Continuous-flow (CF) left ventricular assist devices (LVADs) have become the standard of
care for patients with advanced heart failure refractory to optimal medical therapy. The goal …

Objectives: This study sought to evaluate the use of a continuous-flow rotary left ventricular
assist device (LVAD) as a bridge to heart transplantation. Background: LVAD therapy is an …

Over the last 15 years, the field of mechanical circulatory support (MCS) has enjoyed a rapid
technological evolution, leading to marked gains in patient survival. In 2010, average 1-year …

Feature Editor's Introduction—Durable left ventricular assist device (LVAD) therapy has had
a remarkable evolution over the past 2 decades. Moving from a therapy once confined to …